Former Chief Medical Officer (8) · INOVIO PHARMACEUTICALS, INC. (INO)

Mark Bagarazzi

A named executive officer of INOVIO PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$2,324,930

Salary $214,279Stock awards $199,398

FY2018: $1,345,888

2nd of 5 named executive officers at Inovio Pharmaceuticals by FY2019 total.

5 named officers on file for INOVIO PHARMACEUTICALS, FY2019

Mark Bagarazzi’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 5 equity grants, each cited to its filing
  • INO’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how INOVIO PHARMACEUTICALS’s whole pay program stands against its peers

  • INOVIO PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on INO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 27, 2020 (DEF 14A).

Free

Get Mark Bagarazzi’s full pay file as a PDF — free

More than this page: up to 10 years of Mark’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Mark Bagarazzi compensation by year

INOVIO PHARMACEUTICALS Summary Compensation Table · all 4 fiscal years held
In US dollars, as INOVIO PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019
Salary$408,458$435,053$448,101$214,279
Bonus$0$0$0$0
Stock awards$526,500$409,484$354,783$199,398
Option awards$290,838$437,586$358,612$892,118
Non-equity incentive$156,311$148,750$171,238$0
Pension and deferred compensation$0$0$0$0
All other$11,683$13,846$13,154$1,019,135
Total$1,393,790$1,444,719$1,345,888$2,324,930

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: INOVIO PHARMACEUTICALS, INC. DEF 14A filed March 27, 2020, accession 0001055726-20-000022, and prior-year filings. Open the filing on EDGAR.

How this page was built: the INOVIO PHARMACEUTICALS, INC. filed document, accession 0001055726-20-000022. Every figure is read from that document and cited to the page and table it appears in. Filed March 27, 2020.

$1.4M
$1.4M
$1.3M
$2.3M
FY16
FY17
FY18
FY19
SalaryNon-equity incentiveStock awardsOption awardsAll other

INOVIO PHARMACEUTICALS’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
J KimPresident, Chief Executive Officer and Director$2,588,534
Mark Bagarazzi · this pageFormer Chief Medical Officer (8)$2,324,930
Jacqueline SheaChief Operating Officer (7)$1,157,034
Peter KiesChief Financial Officer$1,142,936
Laurent HumeauChief Scientific Officer (6)$972,531

The full INOVIO PHARMACEUTICALS compensation record

free company brief

This page is one person within INOVIO PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the INOVIO PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are INOVIO PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Mark Bagarazzi's compensation dossier · One-time report. No refunds.